Serum MASP2 level and MASP2 gene polymorphisms in Egyptian systemic lupus erythematosus patients | ||||
| Minia Journal of Medical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 07 October 2024 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2024.305921.1760 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ashraf Mohammed Mohammed Othman1; Hanan Moustafa Kamel2; Naglaa Makram Farag3; Hanaa Ahmed Sadek4; Alaa Ashraf Rashed  5
| ||||
| 1Department of Clinical Pathology, El-Minia Faculty of Medicine | ||||
| 2Professor of Clinical Pathology - Faculty of Medicine, Minia University | ||||
| 3Assistant Professor of Clinical Pathology - Faculty of Medicine, Minia University | ||||
| 4rheumatology an rehabilitaion , faculty university , minia , Egypt | ||||
| 5Assistant lecturer of Clinical Pathology, Clinical Pathology Department, faculty of medicine, El Minia, Egypt | ||||
| Abstract | ||||
| Background:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that predominately affects women. It is characterized by a broad spectrum of clinical manifestations, these manifestations range from fatigue, skin rash, and arthralgia to central nervous system (CNS) involvement, arthritis, serositis, nephritis, pneumonitis, cardiac disease, and hematological problems The aims of the study are:To evaluate the association between MASP2 serum level and SLE disease activity in Egyptian systemic lupus erythematosus patients.To evaluate the association between MASP2 gene polymorphisms (rs17409276, 2273346 and rs1782455) and SLE to determine whether these polymorphisms could be a genetic marker for SLE susceptibility in Egyptian population. Subjects and Methods: Study population :This prospective cohort study was carried out at Clinical Pathology Department, Faculty of Medicine, Minia University. It was conducted on 81 subjects during the period from January 2024 to March 2024.The hospital ethics committee approved this study and a written consent was obtained from patients and controls. (Approval number: 801:08/2021, Date of approval: 16 August 2021). Results:Table I shows that there was no significant difference (p=0.4) between SLE patients and controls regarding their mean age. 97.6% of patients and 48.7% of controls were females, and this difference was statistically significant (p=0001*). As regards residence, there was a statistically significant difference; 71.4% of patients and 97.4% of controls were from urban residences. Conclusions:MASP2 can be considered as a good marker for assessment of SLE activity and severity.MASP2 can be used as an inflammatory marker for SLE. MASP2 gene polymorphism is associated with SLE susceptibility among Egyptian population. | ||||
| Keywords | ||||
| MASP2; Systemic lupus erythematosus; gene polymorphisms | ||||
|
Statistics Article View: 94 |
||||
